Dr. Charlene Fell, University of Calgary, Calgary, AB and
Dr. Janet Pope, Professor of Medicine in the Division of Rheumatology, University of Western Ontario, London, ON

Treatment of ILD from connective tissue diseases has focused on immune suppressive therapies. Antifibrotic treatment may also be of benefit but trials have not yet been reported. In order to effectively identify and treat patients at risk, this symposium will explain the burden of ILD associated with several connective tissue diseases (CTDs) including scleroderma, inflammatory myositis and SLE, and the importance of monitoring patients with CTDs for lung involvement. Screening in scleroderma is established with PFTs performed annually or more often in high risk patients such as Scl70 Ab positive in early disease. Evidence based treatment of CTD-ILD will be discussed. Co-management may include both rheumatologists and respirologists in identification and treatment of these patients.

Learning Objectives
At the end of this session, participants will be able to:

  • understand the burden of ILD associated with connective tissue diseases (CTDs) and the importance of monitoring patients with CTDs for lung involvement;
  • describe the current and emerging treatment of CTD-ILD; and
  • be aware of roles of rheumatologists and respirologists in identification of high risk patients and the management of their disease.

This symposium was co-developed by the CTS and Boehringer Ingelheim and was planned to achieve scientific integrity, objectivity and balance.